Finally, drugs that modulate glutamate signaling are being explored as treatments in non-renal (e.g., brain) diseases (Stone, 2011), and this suggests that similar drugs may ameliorate features of kidney organogenesis associated with HNF1B mutations. The gene discussed is HNF1B; the disease is brain disorder.